BioLineRx to Report 2024 Annual Results on March 31, 2025

Rhea-AI Summary

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, has announced it will release its audited financial results for the year ended December 31, 2024, on Monday, March 31, 2025, before U.S. markets open.

The company will host a conference call at 8:30 a.m. EDT featuring CEO Philip Serlin. Investors can access the call via:

• U.S. dial-in: +1-888-281-1167
• International dial-in: +972-3-918-0685

A live webcast and replay will be available through the company's website. The conference call replay will be accessible until April 2, 2025, via U.S. dial-in (+1-888-295-2634) or international dial-in (+972-3-925-5904).

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, March 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.

 

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. A replay of the call will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until April 2, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  and events.

CONTACTS:

United States     
Irina Koffler
LifeSci Advisors, LLC
ikoffler@lifesciadvisors.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg 

 

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-2024-annual-results-on-march-31-2025-302409115.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx (BLRX) release its 2024 annual financial results?

BioLineRx will release its 2024 annual financial results on Monday, March 31, 2025, before U.S. markets open.

What time is the BioLineRx (BLRX) earnings conference call scheduled for March 31, 2025?

The earnings conference call is scheduled for 8:30 a.m. EDT on March 31, 2025.

How can investors access BioLineRx's (BLRX) 2024 annual results conference call?

Investors can dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally, or access the live webcast through the company's website.

Until when will the replay of BioLineRx's (BLRX) 2024 annual results call be available?

The conference call replay will be available until April 2, 2025, accessible via U.S. and international dial-in numbers.